Avipep's Clinical Study Of AVP-04 In Ovarian And Prostate Cancer Selected For Oral Presentation At AACR
MELBOURNE, Australia & PHILADELPHIA, Pa.--(BUSINESS WIRE)--Australian antibody company Avipep has today announced the clinical results of the imaging study of AVP04, the company’s treatment for advanced prostate and ovarian cancers, will be presented at the world’s largest cancer therapies conference AACR in Philadelphia, USA, on Monday (US EDT).
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.